MANA Advisors LLC acquired a new position in TherapeuticsMD Inc (NASDAQ:TXMD) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,256 shares of the company’s stock, valued at approximately $104,000.
Other hedge funds also recently bought and sold shares of the company. Edge Wealth Management LLC grew its position in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after acquiring an additional 20,000 shares during the last quarter. Quantbot Technologies LP bought a new position in TherapeuticsMD during the third quarter valued at approximately $189,000. Claraphi Advisory Network LLC bought a new position in TherapeuticsMD during the fourth quarter valued at approximately $275,000. Teacher Retirement System of Texas grew its position in TherapeuticsMD by 332.0% during the fourth quarter. Teacher Retirement System of Texas now owns 58,000 shares of the company’s stock valued at $350,000 after acquiring an additional 44,574 shares during the last quarter. Finally, Greenwood Capital Associates LLC grew its position in TherapeuticsMD by 25.9% during the fourth quarter. Greenwood Capital Associates LLC now owns 74,268 shares of the company’s stock valued at $449,000 after acquiring an additional 15,300 shares during the last quarter. Institutional investors own 73.27% of the company’s stock.
TXMD has been the topic of a number of recent research reports. Oppenheimer set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, February 21st. BidaskClub cut shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research report on Friday, February 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 7th. Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. Finally, Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, February 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $14.50.
TherapeuticsMD stock traded down $0.10 during trading hours on Thursday, hitting $5.08. The stock had a trading volume of 679,591 shares, compared to its average volume of 1,826,969. The stock has a market capitalization of $1,103.64, a price-to-earnings ratio of -13.43 and a beta of 1.36. TherapeuticsMD Inc has a 52-week low of $3.50 and a 52-week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. The company had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $4.66 million. During the same period last year, the company posted ($0.12) EPS. The business’s revenue for the quarter was down 8.0% compared to the same quarter last year. sell-side analysts forecast that TherapeuticsMD Inc will post -0.38 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/22/mana-advisors-llc-invests-104000-in-therapeuticsmd-inc-txmd.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.